Patents Assigned to J-Pharma Co., Ltd
-
Publication number: 20250041281Abstract: A treatment agent for the treatment of curatively unresectable biliary tract cancer that has become refractory or intolerant to cancer chemotherapy and has worsened in a subject is disclosed. The method includes administering a composition to a subject in need of the treatment a composition containing an LAT1 inhibitor, wherein the subject is a LAT1-high expressing patient having Non-Rapid N-acetyltransferase 2.Type: ApplicationFiled: July 12, 2024Publication date: February 6, 2025Applicant: J-PHARMA CO., LTD.Inventors: Masuhiro YOSHITAKE, Haruki Kusaka
-
Patent number: 11899019Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.Type: GrantFiled: November 7, 2018Date of Patent: February 13, 2024Assignees: J-PHARMA CO., LTD., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, OSAKA UNIVERSITYInventors: Hitoshi Endou, Goshi Ishihara, Kyoichi Kaira, Yoshikatsu Kanai
-
Publication number: 20220288035Abstract: Provided is a pharmaceutical composition containing O-(5-amino-2-phenylbenzoxazole-7-yl)methyl-3,5-dichloro-L-tyrosine, or a pharmaceutically acceptable salt thereof, for use in treatment of a cancerous disease in a subject, the pharmaceutical composition being administered to the subject having a Non-Rapid (Slow and/or Intermediate) type NAT2 gene.Type: ApplicationFiled: August 31, 2020Publication date: September 15, 2022Applicant: J-PHARMA CO., LTD.Inventors: Masuhiro YOSHITAKE, Yoshinori BAMBA, Hitoshi ENDOU, Tokiko SUZUKI
-
Publication number: 20220288036Abstract: Provided is a pharmaceutical composition including O-(5-amino-2-phenylbenzoxazole-7-yl)methyl-3,5-dichloro-L-tyrosine, or a pharmaceutically acceptable salt thereof, for use in treatment of a disease such as an allergic disease, an autoimmune disease, or an inflammatory disease in a subject, the pharmaceutical composition being administered to the subject having a Non-Rapid (Slow and/or Intermediate) type NAT2 gene.Type: ApplicationFiled: August 31, 2020Publication date: September 15, 2022Applicant: J-PHARMA CO., LTD.Inventors: Masuhiro YOSHITAKE, Yoshinori BAMBA
-
Publication number: 20210231668Abstract: The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.Type: ApplicationFiled: February 5, 2021Publication date: July 29, 2021Applicant: J-Pharma Co., Ltd.Inventors: Nobuyuki Yanagisawa, Isao Okayasu
-
Publication number: 20210148920Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.Type: ApplicationFiled: November 7, 2018Publication date: May 20, 2021Applicants: J-Pharma Co., Ltd., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, OSAKA UNIVERSITYInventors: Hitoshi Endou, Goshi Ishihara, Kyoichi Kaira, Yoshikatsu Kanai
-
Publication number: 20200405695Abstract: O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof exhibits high therapeutic effects on bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, and pancreatic cancer.Type: ApplicationFiled: August 1, 2018Publication date: December 31, 2020Applicant: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Junji Furuse, Isao Okayasu, Michael F. Wempe
-
Publication number: 20190227070Abstract: The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.Type: ApplicationFiled: March 10, 2016Publication date: July 25, 2019Applicant: J-Pharma Co., Ltd.Inventors: Nobuyuki Yanagisawa, Isao Okayasu
-
Patent number: 10173990Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.Type: GrantFiled: December 28, 2015Date of Patent: January 8, 2019Assignees: Nippon Chemiphar Co., Ltd., J-Pharma Co., Ltd., DeThree Res. Lab. Inc.Inventors: Tsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masuharu Hirano, Hitoshi Endou, Naohiko Anzai
-
Patent number: 10172835Abstract: A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.Type: GrantFiled: June 7, 2014Date of Patent: January 8, 2019Assignee: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Michael F. Wempe, Jean-Francois Peyron, Naohiko Anzai, Promsuk Jutabha
-
Patent number: 10005750Abstract: A compound represented by the general Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A-K are individually selected from carbon or nitrogen; X?—O, —NR1, or —S; R1-11 are individually selected from the group consisting of —H, C1-C6 alkyl, C6-C14 aryl, substituted C6-C14 aryl, C1-C14-alkoxy, halogen, hydroxyl, carboxy, cyano, C1-C6-alkanoyloxy, C1-C6-alkylthio, C1-C6-alkylsulfonyl, trifluoromethyl, hydroxy, C2-C6-alkoxycarbonyl, C2-C6-alkanoylamino, —O—R12, S—R12, —SO2—R12, —NHSO2R12 and —NHCO2R12, wherein R12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C1-C6-alkyl, C6-C10 aryl, C1-C6-alkoxy and halogen, and C4-C20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.Type: GrantFiled: October 6, 2011Date of Patent: June 26, 2018Assignee: J-Pharma Co., Ltd.Inventors: Michael F. Wempe, Hitoshi Endou
-
Publication number: 20170290795Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.Type: ApplicationFiled: December 28, 2015Publication date: October 12, 2017Applicant: J-Pharma Co., Ltd.Inventors: Tsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masaharu Hirano, Hitoshi Endou, Naohiko Anzai
-
Patent number: 9618512Abstract: A method for the diagnosis of breast cancer using an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, expresses LAT1 at a significantly high level, as compared to intraductal breast papilloma, which is benign. An anti-LAT1 monoclonal antibody is useful for the discrimination between these two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas, which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer. Therefore, LAT1 can be used as a novel molecular targeting marker for the triple negative breast cancer.Type: GrantFiled: April 13, 2012Date of Patent: April 11, 2017Assignee: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Isao Okayasu
-
Publication number: 20160370379Abstract: A blood-based biomarker for cancer includes a specific amino acid group of at least seven amino acids. The at least seven amino acids include histidine, isoleucine, leucine, methionine, tryptophan, valine, and tyrosine. The specific amino acid group may further include phenylalanine. The cancer is at least one kind of cancer selected from the group consisting of liver cancer, colon cancer, lung cancer, gall bladder cancer, lymph node metastatic cancer, gastric cancer, pancreas cancer, bile duct cancer, breast cancer, malignant mesothelioma, and T-cell leukemia/lymphoma.Type: ApplicationFiled: June 9, 2015Publication date: December 22, 2016Applicant: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Isao Okayasu, Kiyomi Hana
-
Publication number: 20160279103Abstract: A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.Type: ApplicationFiled: June 7, 2014Publication date: September 29, 2016Applicant: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Michael F. Wempe, Jean-Francois Peyron, Naohiko Anzai, Promsuk Jutabha
-
Publication number: 20140106377Abstract: A method for the diagnosis of breast cancer using an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, expresses LAT1 at a significantly high level, as compared to intraductal breast papilloma, which is benign. An anti-LAT1 monoclonal antibody is useful for the discrimination between these two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas, which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer. Therefore, LAT1 can be used as a novel molecular targeting marker for the triple negative breast cancer.Type: ApplicationFiled: April 13, 2012Publication date: April 17, 2014Applicant: J-PHARMA CO., LTD.Inventors: Hitoshi Endou, Isao Okayasu
-
Publication number: 20130225673Abstract: A compound represented by the general Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A-K are individually selected from carbon or nitrogen; X?—O, —NR1, or —S; R1-11 are individually selected from the group consisting of —H, C1-C6 alkyl, C6-C14 aryl, substituted C6-C14 aryl, C1-C14-alkoxy, halogen, hydroxyl, carboxy, cyano, C1-C6-alkanoyloxy, C1-C6-alkylthio, C1-C6-alkylsulfonyl, trifluoromethyl, hydroxy, C2-C6-alkoxycarbonyl, C2-C6-alkanoylamino, —O—R12, S—R12, —SO2—R12, —NHSO2R12 and —NHCO2R12, wherein R12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C1-C6-alkyl, C6-C10 aryl, C1-C6-alkoxy and halogen, and C4-C20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.Type: ApplicationFiled: October 6, 2011Publication date: August 29, 2013Applicant: J-PHARMA CO., LTD.Inventors: Michael F. Wempe, Hitoshi Endou
-
Publication number: 20120100226Abstract: The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present.Type: ApplicationFiled: December 14, 2011Publication date: April 26, 2012Applicant: J-PHARMA CO., LTD.Inventors: Hitoshi Endou, Tomotaka Yanagita, Koji Yamashita
-
Publication number: 20120083588Abstract: The present invention relates to an amino acid transporter protein having the ability to mediate the transport of amino acids into a cell, a gene encoding the protein, an antibody having a reactivity with the protein, a cell which produces the antibody, related kits and methods.Type: ApplicationFiled: February 8, 2010Publication date: April 5, 2012Applicant: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Yoshikatsu Kanai
-
Patent number: 8039586Abstract: A cerebral organic anion transporter OAT3 which is useful as a protein regulating the uptake/excretion of organic anionic substances in the brain; a nucleic acid having a base sequence encoding the same; and an antibody against the same. The amino acid sequence and the base sequence of the above OAT3 are shown in Sequence Listing in the description.Type: GrantFiled: September 20, 1999Date of Patent: October 18, 2011Assignee: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Takashi Sekine, Hiroyuki Kusuhara